Market capitalization | JPY1.69t |
Enterprise Value | JPY1.40t |
P/E (TTM) P/E ratio | 17.63 |
EV/FCF (TTM) EV/FCF | 16.92 |
EV/Sales (TTM) EV/Sales | 2.94 |
P/S ratio (TTM) P/S ratio | 3.55 |
P/B ratio (TTM) P/B ratio | 1.96 |
Dividend yield | 1.81% |
Last dividend (FY24) | JPY58.00 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
11 Analysts have issued a Kyowa Kirin forecast:
11 Analysts have issued a Kyowa Kirin forecast:
Jun '24 |
+/-
%
|
||
Revenue | 475,997 475,997 |
15%
15%
|
|
Gross Profit | 340,984 340,984 |
9%
9%
|
|
EBITDA | 124,105 124,105 |
24%
24%
|
EBIT (Operating Income) EBIT | 100,793 100,793 |
25%
25%
|
Net Profit | 97,318 97,318 |
142%
142%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Masashi Miyamoto |
Employees | 5,974 |
Founded | 1949 |
Website | www.kyowa-kirin.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.